These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33280052)

  • 41. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens.
    Mithani Z; Gralla J; Adebiyi O; Klem P; Cooper JE; Wiseman AC
    Exp Clin Transplant; 2018 Feb; 16(1):23-30. PubMed ID: 28332959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection.
    Gill JS; Landsberg D; Johnston O; Shapiro RJ; Magil AB; Wu V; Tinckam K; Keown P
    Transplantation; 2010 Jan; 89(2):178-84. PubMed ID: 20098280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
    Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
    Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
    Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival.
    Jouve T; Fonrose X; Noble J; Janbon B; Fiard G; Malvezzi P; Stanke-Labesque F; Rostaing L
    Transplantation; 2020 Jun; 104(6):1263-1271. PubMed ID: 31415035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development.
    Rodrigo E; Segundo DS; Fernández-Fresnedo G; López-Hoyos M; Benito A; Ruiz JC; de Cos MA; Arias M
    Transplantation; 2016 Nov; 100(11):2479-2485. PubMed ID: 26703349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tacrolimus Trough Level at the First Month May Predict Renal Transplantation Outcomes Among Living Chinese Kidney Transplant Patients: A Propensity Score-Matched Analysis.
    Yin S; Song T; Jiang Y; Li X; Fan Y; Lin T
    Ther Drug Monit; 2019 Jun; 41(3):308-316. PubMed ID: 31083041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
    Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
    Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Results of early treatment for de novo donor-specific antibodies in pediatric kidney transplant recipients in a cross-sectional and longitudinal cohort.
    Charnaya O; Tuchman S; Moudgil A
    Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29356221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.
    Narumi S; Watarai Y; Goto N; Hiramitsu T; Tsujita M; Okada M; Futamura K; Tomosugi T; Nishihira M; Sakamoto S; Kobayashi T
    Transplant Proc; 2019 Jun; 51(5):1378-1381. PubMed ID: 31056252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sirolimus and tacrolimus coefficient of variation is associated with rejection, donor-specific antibodies, and nonadherence.
    Pizzo HP; Ettenger RB; Gjertson DW; Reed EF; Zhang J; Gritsch HA; Tsai EW
    Pediatr Nephrol; 2016 Dec; 31(12):2345-2352. PubMed ID: 27286686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tacrolimus time-in-therapeutic range is associated with freedom from acute rejection and graft failure following intestinal transplantation.
    Santeusanio AD; Gu A; Weinberg AD; Moon J; Iyer KR
    Clin Transplant; 2021 Jun; 35(6):e14291. PubMed ID: 33740822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
    Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.